Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

STK38 is a critical upstream regulator of MYC's oncogenic activity in human B-cell lymphoma.

Bisikirska BC, Adam SJ, Alvarez MJ, Rajbhandari P, Cox R, Lefebvre C, Wang K, Rieckhof GE, Felsher DW, Califano A.

Oncogene. 2013 Nov 7;32(45):5283-91. doi: 10.1038/onc.2012.543. Epub 2012 Nov 26.

2.

Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state.

den Hollander J, Rimpi S, Doherty JR, Rudelius M, Buck A, Hoellein A, Kremer M, Graf N, Scheerer M, Hall MA, Goga A, von Bubnoff N, Duyster J, Peschel C, Cleveland JL, Nilsson JA, Keller U.

Blood. 2010 Sep 2;116(9):1498-505. doi: 10.1182/blood-2009-11-251074. Epub 2010 Jun 2.

3.

The direct Myc target Pim3 cooperates with other Pim kinases in supporting viability of Myc-induced B-cell lymphomas.

Forshell LP, Li Y, Forshell TZ, Rudelius M, Nilsson L, Keller U, Nilsson J.

Oncotarget. 2011 Jun;2(6):448-60.

4.

Pim1 promotes human prostate cancer cell tumorigenicity and c-MYC transcriptional activity.

Kim J, Roh M, Abdulkadir SA.

BMC Cancer. 2010 Jun 1;10:248. doi: 10.1186/1471-2407-10-248.

5.

Telomerase regulates MYC-driven oncogenesis independent of its reverse transcriptase activity.

Koh CM, Khattar E, Leow SC, Liu CY, Muller J, Ang WX, Li Y, Franzoso G, Li S, Guccione E, Tergaonkar V.

J Clin Invest. 2015 May;125(5):2109-22. doi: 10.1172/JCI79134. Epub 2015 Apr 20.

6.

MINCR is a MYC-induced lncRNA able to modulate MYC's transcriptional network in Burkitt lymphoma cells.

Doose G, Haake A, Bernhart SH, López C, Duggimpudi S, Wojciech F, Bergmann AK, Borkhardt A, Burkhardt B, Claviez A, Dimitrova L, Haas S, Hoell JI, Hummel M, Karsch D, Klapper W, Kleo K, Kretzmer H, Kreuz M, Küppers R, Lawerenz C, Lenze D, Loeffler M, Mantovani-Löffler L, Möller P, Ott G, Richter J, Rohde M, Rosenstiel P, Rosenwald A, Schilhabel M, Schneider M, Scholz I, Stilgenbauer S, Stunnenberg HG, Szczepanowski M, Trümper L, Weniger MA; ICGC MMML-Seq Consortium, Hoffmann S, Siebert R, Iaccarino I.

Proc Natl Acad Sci U S A. 2015 Sep 22;112(38):E5261-70. doi: 10.1073/pnas.1505753112. Epub 2015 Sep 8.

7.

Induction of ectopic Myc target gene JAG2 augments hypoxic growth and tumorigenesis in a human B-cell model.

Yustein JT, Liu YC, Gao P, Jie C, Le A, Vuica-Ross M, Chng WJ, Eberhart CG, Bergsagel PL, Dang CV.

Proc Natl Acad Sci U S A. 2010 Feb 23;107(8):3534-9. doi: 10.1073/pnas.0901230107. Epub 2010 Feb 2.

8.

The IKK2/NF-{kappa}B pathway suppresses MYC-induced lymphomagenesis.

Klapproth K, Sander S, Marinkovic D, Baumann B, Wirth T.

Blood. 2009 Sep 17;114(12):2448-58. doi: 10.1182/blood-2008-09-181008. Epub 2009 Jul 23.

9.

Synergistic effect of Bcl2, Myc and Ccnd1 transforms mouse primary B cells into malignant cells.

Nakagawa M, Tsuzuki S, Honma K, Taguchi O, Seto M.

Haematologica. 2011 Sep;96(9):1318-26. doi: 10.3324/haematol.2011.041053. Epub 2011 May 23.

10.

Targeting ornithine decarboxylase in Myc-induced lymphomagenesis prevents tumor formation.

Nilsson JA, Keller UB, Baudino TA, Yang C, Norton S, Old JA, Nilsson LM, Neale G, Kramer DL, Porter CW, Cleveland JL.

Cancer Cell. 2005 May;7(5):433-44.

11.

Epstein-Barr virus latent membrane protein 2A enhances MYC-driven cell cycle progression in a mouse model of B lymphoma.

Fish K, Chen J, Longnecker R.

Blood. 2014 Jan 23;123(4):530-40. doi: 10.1182/blood-2013-07-517649. Epub 2013 Oct 30.

12.

Suppression of Aurora-A oncogenic potential by c-Myc downregulation.

Yang S, He S, Zhou X, Liu M, Zhu H, Wang Y, Zhang W, Yan S, Quan L, Bai J, Xu N.

Exp Mol Med. 2010 Nov 30;42(11):759-67.

14.

CD19 is a major B cell receptor-independent activator of MYC-driven B-lymphomagenesis.

Chung EY, Psathas JN, Yu D, Li Y, Weiss MJ, Thomas-Tikhonenko A.

J Clin Invest. 2012 Jun;122(6):2257-66. doi: 10.1172/JCI45851. Epub 2012 May 1.

15.

Endogenous Bcl-xL is essential for Myc-driven lymphomagenesis in mice.

Kelly PN, Grabow S, Delbridge AR, Strasser A, Adams JM.

Blood. 2011 Dec 8;118(24):6380-6. doi: 10.1182/blood-2011-07-367672. Epub 2011 Oct 12.

16.

Tristetraprolin impairs myc-induced lymphoma and abolishes the malignant state.

Rounbehler RJ, Fallahi M, Yang C, Steeves MA, Li W, Doherty JR, Schaub FX, Sanduja S, Dixon DA, Blackshear PJ, Cleveland JL.

Cell. 2012 Aug 3;150(3):563-74. doi: 10.1016/j.cell.2012.06.033.

17.

MicroRNA-146a modulates B-cell oncogenesis by regulating Egr1.

Contreras JR, Palanichamy JK, Tran TM, Fernando TR, Rodriguez-Malave NI, Goswami N, Arboleda VA, Casero D, Rao DS.

Oncotarget. 2015 May 10;6(13):11023-37.

18.

DYRK2 priming phosphorylation of c-Jun and c-Myc modulates cell cycle progression in human cancer cells.

Taira N, Mimoto R, Kurata M, Yamaguchi T, Kitagawa M, Miki Y, Yoshida K.

J Clin Invest. 2012 Mar;122(3):859-72. doi: 10.1172/JCI60818. Epub 2012 Feb 6.

19.

Selective transcriptional regulation by Myc in cellular growth control and lymphomagenesis.

Sabò A, Kress TR, Pelizzola M, de Pretis S, Gorski MM, Tesi A, Morelli MJ, Bora P, Doni M, Verrecchia A, Tonelli C, Fagà G, Bianchi V, Ronchi A, Low D, Müller H, Guccione E, Campaner S, Amati B.

Nature. 2014 Jul 24;511(7510):488-492. doi: 10.1038/nature13537. Epub 2014 Jul 9.

20.

Suppression of Ras/Mapk pathway signaling inhibits Myc-induced lymphomagenesis.

Gramling MW, Eischen CM.

Cell Death Differ. 2012 Jul;19(7):1220-7. doi: 10.1038/cdd.2012.1. Epub 2012 Feb 3.

Supplemental Content

Support Center